PriceTargets.com logo

NASDAQ:INM - InMed Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.00
  • Forecasted Upside: 1,433.74 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.39 As of 08/12/2022 06:25 PM ET
▼ -0.0061 (-1.54%)

This chart shows the closing price for INM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New InMed Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INM

Analyst Price Target is $6.00
▲ +1,433.74% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for InMed Pharmaceuticals in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 1,433.74% upside from the last price of $0.39.

This chart shows the closing price for INM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in InMed Pharmaceuticals. This rating has held steady since November 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/17/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/14/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/12/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2022Roth CapitalDowngradeBuy ➝ NeutralHigh
2/15/2022Roth CapitalReiterated RatingBuyHigh
11/29/2021HC WainwrightInitiated CoverageBuy$6.00High
5/14/2021Roth CapitalReiterated RatingBuy$11.50Low
2/16/2021Roth CapitalLower Price TargetBuy$12.00 ➝ $11.50Low
1/29/2021Roth CapitalReiterated RatingBuyLow
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/14/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/13/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/15/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/14/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/14/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/13/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/13/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/12/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
InMed Pharmaceuticals logo
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: $0.39
Low: $0.38
High: $0.44

50 Day Range

MA: $0.47
Low: $0.36
High: $0.68

52 Week Range

Now: $0.39
Low: $0.34
High: $2.59

Volume

191,328 shs

Average Volume

173,642 shs

Market Capitalization

$6.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.3

Frequently Asked Questions

What sell-side analysts currently cover shares of InMed Pharmaceuticals?

The following Wall Street analysts have issued reports on InMed Pharmaceuticals in the last year: HC Wainwright, and Roth Capital.
View the latest analyst ratings for INM.

What is the current price target for InMed Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for InMed Pharmaceuticals in the last year. Their average twelve-month price target is $6.00, suggesting a possible upside of 1,433.7%. HC Wainwright has the highest price target set, predicting INM will reach $6.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $6.00 for InMed Pharmaceuticals in the next year.
View the latest price targets for INM.

What is the current consensus analyst rating for InMed Pharmaceuticals?

InMed Pharmaceuticals currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INM will outperform the market and that investors should add to their positions of InMed Pharmaceuticals.
View the latest ratings for INM.

What other companies compete with InMed Pharmaceuticals?

Other companies that are similar to InMed Pharmaceuticals include Avenue Therapeutics, Benitec Biopharma, Advaxis, Enveric Biosciences and Altamira Therapeutics. Learn More about companies similar to InMed Pharmaceuticals.

How do I contact InMed Pharmaceuticals' investor relations team?

The company's listed phone number is 604-669-7207 and its investor relations email address is [email protected] The official website for InMed Pharmaceuticals is www.inmedpharma.com. Learn More about contacing InMed Pharmaceuticals investor relations.